AQUIPTA™ is indicated for prophylaxis
of migraine in adults who have at least
4 migraine days per month.1
Once-daily tablet1 that is simple to take
AQUIPTA™ is indicated for prophylaxis of migraine in adults
who have at least 4 migraine days per month.1
Half-life: approximately 11 hours1
Dose modification
10 mg once daily is recommended in patients:1
- Taking concomitant strong organic anion transporting polypeptide (OATP) inhibitors
- Taking concomitant strong cytochrome P450 3A4 (CYP3A4) inhibitors
- With severe renal impairment (creatinine clearance [CrCl] 15–29 mL/min), or end-stage renal disease (CrCl <15 mL/min)
- For patients with end-stage renal disease undergoing intermittent dialysis, AQUIPTA™ should preferably be taken after dialysis
Precautions and contraindications
- AQUIPTA™ should be avoided in patients with severe hepatic impairment1
- AQUIPTA™ is not recommended during pregnancy and in women of childbearing potential not using contraception1
- AQUIPTA™ is contraindicated in anyone with hypersensitivity to the active substance or any of the excipients listed in Section 6.1 of the SmPC1
CrCl, creatinine clearance; CYP3A4, cytochrome P450 3A4; IE, Ireland; OATP, organic anion transporting polypeptide.
Reference:
- AQUIPTA™ (atogepant) IE Summary of Product Characteristics. August 2023.
ALL-AQP-230003 March 2024